e-Therapeutics plc (ETX.L)

22.00 +1.00 (+4.76%) At close: 02:47PM BST

e-Therapeutics plc

4 Kingdom Street
Floor 4 Unit 4B Paddington Central
London W2 6BD
United Kingdom
44 20 4551 8888
https://www.etherapeutics.co.uk

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 35

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Ahmad Ali Mortazavi	CEO & Director	348k	N/A	1971
Mr. Michael Anthony Bretherton ACA, B.A.	Acting Interim CFO & Director	53k	N/A	1955
Mr. Jonny Wray Ph.D.	Chief Technology Officer	N/A	N/A	N/A
Mr. Alan Whitmore B.Sc., Ph.D.	Chief Scientific Officer	N/A	N/A	N/A
Ms. Sarah Clare	Director of Fin. & Compliance	N/A	N/A	N/A
Ms. Stephanie Maley CIPD	Chief People Officer	N/A	N/A	N/A
Dr. Laura Roca-Alonso Ph.D.	Chief Bus. Officer	N/A	N/A	N/A
Ms. Alison Gallafent	Chief Intellectual Property Officer	N/A	N/A	N/A
Mr. Ankit Sharma	Head of Software Engineering	N/A	N/A	N/A
Mr. Graham Craggs	Head of Therapeutic Discovery	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

e-Therapeutics plc engages in drug discovery research activities in the United Kingdom. Its computational platform provides in silico screens generate predictions on compounds and/or targets that can have a significant perturbative effect on the biology of interest, captured by its network models, as well as developing RNAi platform for highly specific gene silencing. The company was incorporated in 2001 and is based in London, the United Kingdom.

Corporate governance

e-Therapeutics plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.